Patent intelligence · EP
EP 4529925
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN
Patent details — EP 4529925
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Apr 2, 2025
- Expiration
- Mar 28, 2045
- Applicant
- CASSIOPEA S P A [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 573 A I, A61K/31573, A61K/4706
Quick answer
EP 4529925 (CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Apr 2, 2025. Expires Mar 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASSIOPEA S P A [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 573 A I, A61K/31573, A61K/4706, A61K/4710, A61K/4714
Frequently asked questions
What is US patent 4529925?
EP 4529925 (CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN) is held by CASSIOPEA S P A [IT]. Status: granted. Granted Apr 2, 2025. Expires Mar 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4529925?
CASSIOPEA S P A [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews.
When does EP 4529925 expire?
Our index shows an expiration date of Mar 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.